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A proof-of-concept aptamer-based optical assay is described for the determination of the 
immune signalling molecule interleukin-6 (IL-6), a key marker of acute inflammation. The 
optical assay is based on the aggregation of gold nanoparticles (AuNP) coated in two 
complimentary “sandwich-style” aptamers, each with different IL-6 target moieties. IL-6 will 
recognise the complimentary aptamer pair and bind to it causing the aggregation of the 
corresponding functionalised nanoparticles. The aggregation of the AuNPs after exposure to 
IL-6 induces a visible colour change from red to pink, with a corresponding change in the 
extinction maximum from 520 to 540 nm. The change in the extinction maximum can be 
monitored visually, or using a spectrophotometer or a plate reader. The optimal size and 
functionalisation method of aptamer-coated AuNP, and potential assay format were 
investigated using UV-Vis spectrophotometry, transmission electron microscopy, and dynamic 
light scattering. The optical assay was applied for detecting mouse IL-6 in a mixed protein 
solution as a representative biological sample. The assay works in the 3.3 to 125 µg·mL-1 IL-
6 concentration range, and the detection limit (at S/N = 3) is 1.95 µg·mL-1. This study was 
performed as a proof-of-concept demonstration of this versatile assay design, with a view to 




Schematic representation of the aggregation of aptamer-functionalised nanoparticles in the 
presence of interleukin-6 (IL-6). The presence of mouse IL-6 in a mixed protein solution 





Key words:  




Inflammation, the body’s immune response to infection or injury, plays a key role in almost all 
pathological conditions. Inflammation is mediated by immune molecules which act as chemical 
messengers yielding a response from other cells. Different types of immune molecules have 
been associated with driving inflammation, or a redirection to a healing function. There is 
increasing evidence that early detection of inflammatory molecules can enable timely clinical 
intervention with potentially life-saving consequences for patients. This is particularly true for 
pathological conditions in hidden environments such as the brain, where changes in 
inflammatory processes are not always immediately obvious from a clinical perspective.  
Interleukin-6 (IL-6) is an immune molecule associated with acute inflammation, particularly in 
response to recent infection or injury [1]. High levels of IL-6 measured in cerebrospinal fluid 
(CSF) and plasma have been associated with pathological inflammation leading to poor 
clinical outcome in patients with brain injuries, such as traumatic brain injury (TBI) [2, 3] and 
subarachnoid haemorrhage (SAH) [4, 5]. IL-6 above a certain threshold in CSF drain samples 
has been recognised as a potentially important diagnostic marker of bacterial meningitis [6]. 
Bedside detection of raised IL-6 would potentially enable rapid treatment of meningitis with 
anti-inflammatory steroids, thereby decreasing the risk of mortality [6, 7]. IL-6 can also be used 
as an early indicator of potentially life-threatening infection. Sepsis, which is systemic, 
uncontrolled inflammation caused by the body’s reaction to infection, is one of the most 
common causes of deaths in a hospital environment, and is especially common in the elderly 
[8]. Conventional diagnosis of sepsis relies on recognition of infection, which can be 
challenging in comatose patients. Positive microbiological cultures (which can take days) 
remains the gold standard for diagnosis, along with key clinical assessments including 
temperature, white cell count (WCC), C-reactive protein (CRP), and blood lactate [9, 10]. 
Significant developments in the field of sepsis diagnosis attempt to address the lengthy time 
required to perform blood cultures. These include new real-time PCR, multiplex PCR-based 
assays, and microarray techniques for pathogen identification directly from blood. Although 
these new methods enable more rapid diagnosis, current limitations include high cost (£140-
£160/test) and specialised laboratory equipment requirements [11]. Bedside detection of 
raised IL-6 levels in the blood would aid the diagnosis of infection, thereby enabling the fast 
and effective treatment necessary to combat this disease [8, 10, 12]. 
The growing trend for transition of diagnostic tests from the laboratory to the point-of-care 
reflects the mounting evidence that early detection of changes in the body enable rapid clinical 
intervention with maximum benefit. This is particularly relevant in cases of increased 
inflammation. Current commercially available technology employs antibodies as detection 
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agents, in both the clinical laboratory, and in point-of-care diagnostics. An example is a 
bedside interleukin-6 test for the early detection of infection in expectant mothers, to prevent 
pre-term births [13]. This test uses antibodies to bind IL-6 and enable detection. Antibodies 
are used as the recognition unit in the majority of methods reported in the literature that could 
be potentially apply for the detection of IL-6 in clinical diagnosis (Table S1). Antibodies are 
mass-produced in animals, hybridoma cell ines or genetically-modified bacteria, with the 
inherent risk of inter-batch variability; they require refrigerated storage and specific conditions 
for optimal performance, and they can degrade with time, giving them limited shelf-life. These 
disadvantages can limit the practicality of antibody-based tests, and seeking alternatives to 
antibodies is therefore of tremendous importance. Active research in this area has led to the 
development of an automated system for the synthetic production of aptamers, short DNA 
strands. Aptamers are tuneable and enable high-affinity binding, resulting in improved assay 
sensitivity [14, 15]. Crucially, their synthetic method of production means that they are cheaper 
to produce, and chemically identical than antibodies. Aptamers are also more stable than 
antibodies and can be stored for long periods without refrigeration [16]. The use of aptamers 
in place of antibodies can potentially improve test sensitivity over current state-of-the-art 
bedside tests, and enable smaller sample volumes to be analysed. 
The physical properties of gold nanoparticles (AuNP) cause them to be brightly coloured in 
solution, and this colour visibly changes in response to AuNP aggregation. Diagnostic tests 
based on the aggregation of AuNP have been demonstrated as highly effective for the 
detection of toxins, bacteria, viruses (in allantoic fluid), and immune molecules in human 
biological samples [17-19]. Tests of this nature offer significant advantages over the current 
state-of-the-art in terms of sensitivity, reliability, cost, and easy storage without refrigeration. 
They are particularly practical in a bedside setting as they can be performed quickly and easily 
(in 20 min or less) at room temperature and without sample pre-treatment [20]. AuNPs 
functionalised with heparin have been recently reported for enhanced microdialysis sampling 
of cytokines [21].  
In the present study, we report the development and preliminary trial of a proof-of-concept 
version of a novel bedside test for the detection of IL-6 in biological samples from patients with 
brain injury or infection. The test is based on AuNP functionalised with a ‘sandwich-pair’ of 
aptamers specific for murine IL-6. To the best of our knowledge, this is the first time that a 
‘sandwich-pair’ of aptamers is reported for the optical detection of IL-6 using gold 
nanoparticles. The presence of IL-6, which binds to multiple aptamers on the AuNP surface, 
results in aggregation of the AuNP as schematically shown in Fig. 1. In this pilot study, the 
optical assay was applied for the detection of mouse IL-6 in a mixed protein solution as a 
representative biological sample matrix as an initial proof-of-concept. With further 
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development, the new technique may be applicable for the rapid and straightforward detection 
of acute inflammation in either a mouse model, or in mouse-derived cell culture supernatant. 
The test is performed without previous sample treatment and requires only 5 minutes to 
complete, making it useful in a wide range of clinical settings. The assay design is versatile. 
In future, it may be adapted to a ‘dip-stick’ format. 
 
Fig. 1 A schematic of the aptamer-gold nanoparticle-based aggregation assay for the 




Materials and equipment 
High-purity deionised water (dH2O) used was of HPLC-grade (18.2 MΩ·cm, Millipore Direct 
Q5 UV water purification system with LC-Pak polisher, https://www.merckmillipore.com). All 
reagents were of analytical grade, purchased from Sigma-Aldrich (Poole, Dorset, UK, 
https://www.sigmaaldrich.com) and used as received unless otherwise stated. Millipore Millex-
HV PVDF syringe filter units (0.45 µm) and Millipore Amicon Ultra 0.5 mL centrifuge units 
(100k MWCO) were also purchased from Sigma-Aldrich (Poole, Dorset, UK, 
https://www.sigmaaldrich.com). Sodium phosphate dibasic, sodium chloride, sodium dodecyl 
sulfate (SDS), and potassium chloride were purchased from BDH Laboratory Supplies (Poole, 
UK, https://www.coleparmer.co.uk). 1.5 mL and 5 mL Lo-bind Eppendorf tubes were 
purchased from Thermo Fisher (Loughborough, UK, https://www.thermofisher.com). 
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Recombinant murine IL-6 standard was purchased from PeproTech (London, UK, 
https://www.peprotech.com). Complementary sandwich pair anti-murine IL-6 aptamers 
(ATW0082 and ATW0077, with terminal thiol-modification) and buffers (resuspension buffer 
and, aptamer reducing buffer) were purchased from BasePair Biotechnologies Inc. (Pearland, 
Texas, USA, https://www.basepairbio.com). Holey carbon film 300 mesh copper grids were 
purchased from Agar Scientific (Stansted, UK, http://www.agarscientific.com). ProcartaPlex 
human cytokine and chemokine standard mixes A and B, and Universal Assay Buffer were 
purchased from Affymetrix eBioscience (Hatfield, UK, https://www.thermofisher.com). 
All centrifugation steps were performed using a Hettich 320R centrifuge. Gentle agitation was 
achieved using a Grant-Bio PS-3D Sunflower mini-shaker. Citrate AuNP (cAuNP) synthesis 
was performed using a VWR hotplate magnetic stirrer with temperature probe. UV-Vis 
extinction spectra (200-800 nm) were recorded on a Hitachi U-3000 spectrophotometer at 
room temperature. Quartz cuvettes with a 1 cm path length were used. Transmission electron 
microscope (TEM) images were obtained using a FEI Tecnai F20 FEGTEM operating at 200 
kV. Dynamic light scattering (DLS) measurements of the 15 nm cAuNP were performed on a 
Malvern Zetasizer Nano ZSP (running on Zetasizer 7.12 software). Measurement time, 
attenuation factor and detector position were set as automatic. All other DLS measurements 
were performed using a Wyatt Technologies DynoPro (DLS) Plate Reader II with Corning 96-
well plastic-bottom plates (provided by Wyatt Technologies).  
 
AuNP synthesis and characterisation 
Citrate-stabilised gold nanoparticles (cAuNP) of ca. 15 nm were synthesised according to the 
method of Turkevich et al. [22]. Experimental details are given in the Electronic Supporting 
Material.  
Synthesis of ca. 50 nm cAuNP was performed using the seeded growth method (for AuNPs 
of up to 180 nm) of Bastús et al. [23]. Experimental details are given in the Electronic 
Supporting Material.  
 
Preparation of aptamer-functionalised AuNP 
15 and 50 nm cAuNP were functionalised with thiolated aptamers using the pH-assisted and 
surfactant-free method previously reported by Zhang et al. [24, 25]. The thiolated aptamers 
were first resuspended, folded, and reduced in accordance with the manufacturers’ 
instructions. Briefly, the lyophilised aptamers (as received from the manufacturer) were each 
reconstituted in ‘resuspension buffer’ to 100 µM. The aptamers were diluted to 1:2 (50 µM) in 
phosphate-buffered saline (PBS) (10 mM phosphate buffer, 2.7 mM potassium chloride, 137 
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mM sodium chloride, pH 7.4; with 1 mM MgCl2). Folding was performed by heating the 
aptamers to 95 °C for 5 min, before cooling slowly at room temperature for 15 min. A 1:1 
volume ratio of ‘aptamer reducing buffer’ was added to each aptamer solution, followed by a 
10 min incubation at room temperature. The aptamers were then diluted to a working 
concentration (either 22 or 28 µM) in trisodium citrate (10 mM, pH 3.0) for addition to the 
cAuNP.  
Aptamer-functionalised ca. 15 nm AuNP were prepared by adding the aptamers (31.5 µL of a 
22 µM solution, prepared as described previously) to an aliquot of 15 nm cAuNP (1.5 mL) in 
a 1.5 mL Eppendorf tube. For AuNP functionalised with both aptamers on the same particle, 
the stock solutions of each aptamer (prepared as described above) were mixed (using a 1:1 
ratio) prior to addition to the cAuNP. After addition of the aptamers, the solution was then 
pipette-mixed and left standing for 1 min at room temperature. Trisodium citrate (30 µL of a 
500 µM solution, pH 3.0) was added to the AuNP and pipette-mixed, followed by a 10 min 
incubation at room temperature. NaCl (52.5 µL of a 2 M solution) was then slowly added (drop-
wise). The solution was then mixed by pipette and incubated for 20 min on a 3D shaker (60 
rpm) at room temperature. The solution, red in colour, was treated with more NaCl (150 µL of 
a 2 M solution, added dropwise). The solution was then mixed by pipette once again, and 
incubated for 40 min on a 3D shaker (60 rpm) at room temperature. The aptamer-AuNP were 
then washed three times to remove any unconjugated aptamers. The solution was centrifuged 
at 8,000 rpm for 30 min in 100k MWCO ultrafiltration tubes. After the first centrifugation step, 
the aptamer-AuNP were resuspended in 1.5 mL PB (10 mM, pH 7.4) with 0.05% w/v tween-
20. After the remaining centrifugation steps (and for storage), the aptamer-AuNP were 
resuspended in 1.5 mL PBS (10 mM phosphate buffer, 2.7 mM potassium chloride, 137 mM 
sodium chloride, pH 7.4, 1 mM MgCl2). Modification of the AuNP surface was determined by 
UV-Vis spectrophotometry at ca. 520 nm. The ca. 15 nm aptamer-AuNP were then stored at 
4 °C before use. 
Aptamer-functionalised ca. 50 nm AuNP were prepared by adding the aptamers (180 µL of a 
28 µM solution, prepared as described previously) to an aliquot of 50 nm cAuNP (2 mL) in a 
5 mL Lo-bind Eppendorf tube. For AuNP functionalised with both aptamers on the same 
particle, the stock solutions of each aptamer (prepared as described above) were mixed (using 
a 1:1 ratio) prior to addition to the cAuNP. After addition of the aptamers, the solution was then 
pipette-mixed and left standing for 1 min at room temperature. Trisodium citrate (100 µL of a 
500 µM solution, pH 3.0) was added to the AuNP and pipette-mixed, followed by a 10 min 
incubation at room temperature. NaCl (70 µL of a 2 M solution) was then slowly added (drop-
wise). The solution was then mixed by pipette and incubated for 20 min on a 3D shaker (60 
rpm) at room temperature. The solution, red in colour, was treated with more NaCl (200 µL of 
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a 2 M solution, added drop-wise). The solution was then mixed by pipette once again, and 
incubated for 40 min on a 3D shaker (60 rpm) at room temperature. The aptamer-AuNP were 
then washed three times to remove any unconjugated aptamers. The solution was then 
aliquoted into two 2 mL Eppendorf tubes, and centrifuged at 4,000 rpm for 15 min to form a 
pellet. After the first centrifugation step, the aptamer-AuNP were resuspended in 2 mL PB (10 
mM, pH 7.4) with 0.05% w/v tween-20. After the remaining centrifugation steps (and for 
storage), the aptamer-AuNP were resuspended in 2 mL 1X PBS buffer (pH 7.4, 1 mM MgCl2). 
Modification of the AuNP surface was determined by UV-Vis spectrophotometry at ca. 540 
nm. The ca. 50 nm aptamer-AuNP were then stored at 4 °C before use. 
 
IL-6 aggregation assays and characterisation by DLS 
Aggregation assays were performed by adding increasing concentrations of IL-6 (step-wise, 
from 0 to ≤ 125 µg·mL-1) into a sample of aptamer-AuNP (300 µL) in a cuvette. For single-
aptamer-AuNP, equal volumes of aptamer-AuNP 1 and aptamer-AuNP 2 were first combined 
in a cuvette and mixed prior to IL-6 titration. For mixed-aptamer-AuNP the solution was used 
as prepared. A UV-Vis spectrum was measured before the addition of the IL-6, and 5 min after 
each subsequent addition. The 5 min incubation prior to each measurement was performed 
by capping the cuvette and placing it on a 3D shaker (60 rpm) at room temperature. In order 
to control for the dilution effect, a buffer control was performed alongside the IL-6 test, in which 
equal volumes of the diluent (without IL-6) were added prior to measurement.  
Once the assay had been successfully applied for the measurement of IL-6 in buffer, the 
aggregation assays were repeated on IL-6 in a representative biological matrix. All conditions 
of the experiments were performed using the same protocol as for the titration of IL-6 in buffer 
(as specified above), including the 5 min incubation period at room temperature with light 
agitation prior to measuring. This matrix comprised of a mixed protein solution containing 0.5 
mg·mL-1 human serum albumin (HSA) and 34 human cytokines a chemokines, was prepared 
as follows. The ProcartaPlex mixed human cytokine/chemokine standards (A and B), received 
as lyophilised powders, were resuspended in accordance with the manufacturers’ instructions. 
Subsequently, the standards were diluted to 1:100 in ProcartaPlex Universal Assay Buffer with 
0.5 mg·mL-1 HSA. The cytokine and chemokine concentrations of this matrix solution are as 
shown in the Electronic Supporting Material (Table S2). For the test, murine IL-6 standard (as 
a 1 mg·mL-1 stock solution in dH2O) was added to the matrix prior to titration. For the negative 
control, an equal volume of dH2O (without murine IL-6) was added to the matrix solution prior 
to testing. A buffer control, consisting of ProcartaPlex Universal Assay Buffer with 0.5 mg·mL-
1 HSA (without additional proteins), was also tested to check for cross-reactivity with the 
human proteins.   
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Upon completion of the aggregation assays, aptamer-AuNP and aggregation assay particle 




Results and Discussion 
AuNP synthesis and characterisation 
cAuNP were synthesised according to the citrate reduction methods of Turkevich et al. (ca. 
15 nm) and Bastús et al. (ca. 50 nm), as described in the Electronic Supporting Material [22, 
23]. The average diameters of the cAuNP, measured from TEM images, are 15.0 ± 1.3 nm 
and 53.0 ± 5.2 nm (n = 100) (Fig. S1).  
The cAuNP were functionalised with thiolated aptamers via the pH-assisted method of Zhang 
et al. as described in the Electronic Supporting Material [24, 25]. The binding of the aptamers 
to the surface of the AuNP is demonstrated by a shift in the extinction wavelength of 
approximately 3-4 nm following functionalisation. The UV-Vis extinction spectra that support 
this statement are shown in Fig. S1c and f for 15 nm and 50 nm AuNPs, respectively. This 
shift to the red region of the spectrum is indicative of modification of the surface of the AuNP, 
resulting in a size increase which is reflected by increased extinction wavelength. The increase 
in particle size following addition of aptamers to the AuNP surface was also determined by 
DLS, yielding an average size increase (post-functionalisation) of 38.8 ± 5.1 nm (see Table 
S3 for complete DLS results). These results combined confirm the successful addition of 
aptamers to the particle surface. 
 
Aggregation assay - preliminary development 
Two main aspects of the aggregation assay thought to improve assay performance are 
investigated during this study: i) the size of the AuNP core, and ii) the arrangement of the 
aptamers on the AuNP surface. The effect of AuNP core size on aggregation is initially 
investigated, in line with the findings of Krpetić et al. who showed that larger AuNP elicited an 
improved response in aggregation-based assays [26]. Here two sizes of AuNP are trialled; 
smaller ca. 15 nm AuNP, and larger ca. 50 nm AuNP. The aptamer-AuNP used for these 
experiments are functionalised in a single (rather than mixed) arrangement, yielding two AuNP 
solutions - AuNP-aptamer 1 and AuNP-aptamer 2. Equal volumes of the two functionalised 
AuNP solutions are then combined and mixed in a quartz cuvette (using a 1:1 ratio) prior to 
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IL-6 addition and measurement (as detailed in the Methods section). Increasing volumes of 
IL-6 standard (diluted in PBS, (10 mM phosphate buffer, 2.7 mM potassium chloride, 137 mM 
sodium chloride, pH 7.4) are then titrated into the solutions of aptamer-AuNP. After a 5 min 
incubation at room temperature, the test is complete and a UV-Vis extinction spectrum is taken 
after each addition of IL-6. Aggregation of the AuNP in the presence of IL-6 is indicated by a 
decrease in extinction intensity and a shift in the maximum wavelength.  
Examples of decreasing peak absorption (of the aptamer-AuNP) in response to increasing 
concentrations of IL-6 from these initial tests are shown in Fig. 2a and c (for 15 and 50 nm 
aptamer-AuNP, respectively). It is hypothesised that, by using AuNP with a larger core size, 
the response to IL-6 in the μg·mL-1 range would be improved. The results show that for the 
smaller AuNP core-size (Fig. 2b), the response is not readily distinguishable from the control 
(in which equal volumes of buffer were added instead of IL-6). A shift in the wavelength 
maximum occurs in response to the addition of IL-6 (indicating enlarging of the particles, and 
therefore suggesting aggregation). For example, for the 15 nm AuNP core size, this shift is 4 
nm after addition of IL-6 to 56.6 μg·mL-1 (compared to a 1.0 nm shift for the buffer control) in 
the experiment shown in Fig. 2. For the larger AuNP size, the IL-6 response (in terms of the 
decrease in extinction intensity) is noticeably different from the control (Fig. 2d) even at lower 
IL-6 concentrations (56.6 μg·mL-1 for 15 nm and 22 μg·mL-1 for 50 nm). It should be noted that 
a low concentration of 50 nm aptamer-AuNP (ca. 0.01 nM) is used in this experiment. A shift 
in the wavelength maximum of 4 nm (compared to a 1.5 nm shift for the buffer control) is again 
achieved in the experiment shown in Fig. 2. This time, half the concentration of IL-6 is used 
when compared with that used for the 15 nm AuNP core size. This response is also observed 
during repeat experiments (n = 2). It is therefore concluded that the 50 nm AuNP core size 
yielded an improved assay response in terms of particle aggregation when compared to 
smaller AuNP. Based on these results, and those of the previous set of experiments, 50 nm 




Fig. 2 Comparing the effects of AuNP core size on IL-6 induced aggregation: 15 versus 50 
nm (single) aptamer-AuNP. UV-Vis extinction spectra showing the decrease in the surface 
plasmon absorption band intensity in response to increasing concentrations of IL-6 for the 15 
nm aptamer-AuNP (a) and for the 50 nm aptamer-AuNP (c). Aptamer-AuNP concentrations 
prior to IL-6 addition are an estimated 2.21 nM and 0.01 nM for the 15 nm and 50 nm 
aptamer-AuNP, respectively. Changes in the extinction intensity of 15 nm aptamer-AuNP (b, 
blue) and 50 nm aptamer-AuNP (d, blue) at the maximum wavelength with increasing 
concentrations of IL-6 are compared with those changes observed following addition of a 
buffer control (b and d red, respectively). Results shown are from a single set of 
experiments, representative of all repeats (n = 2) 
 
Experiments are also performed to determine whether AuNP functionalised with a single 
aptamer, or a mixture of both aptamers (in an approximate 1:1 ratio) would improve 
aggregation and test response. It is hypothesised that by co-functionalising the AuNP with 
12 
 
both aptamers, this would improve the rate of aggregation by increasing the number of 
possible binding arrangements and preventing steric hindrance. For the co-functionalised 
AuNP, a 1:1 ratio of the two aptamers on the AuNP surface is assumed based on the equal 
amount of each aptamer applied during functionalisation (as detailed in the methods section). 
Complete characterisation of the resulting ratio was not performed as part of this pilot study. 
The titration of IL-6 was performed as described in the previous experiments. 
Results from an example experiment conducted using 50 nm-sized AuNP are shown in Fig. 
3. Here the results shown are expressed as extinction at 540 nm normalised to AuNP 
concentration, to enable direct comparison with the control aptamer-AuNP 1 with the mixed 
aptamer-AuNP in Fig. 3a (the same units are used in Fig. 3b for consistency). For the single-
aptamer-AuNP (Fig. 3a), the level of aggregation is not readily distinguishable from the binding 
control (in which only one of the two aptamer-AuNP required for aggregation was present). 
However, for the mixed-aptamer-AuNP, the IL-6 response is markedly different from the buffer 
control (Fig. 3b). The mixed-aptamer-AuNP therefore yields more aggregation when 
compared to the single-aptamer-AuNP, suggesting that a greater number of binding 
opportunities do improve the response of the test. This improved response is also observed 
during repeat experiments using ca. 50 nm-sized AuNP (n = 2). Similar experiments are 
performed using ca. 15 nm sized AuNP. The effects of co-functionalisation on AuNP of this 
size is less obvious than with the larger sized AuNP due to the lower degree of aggregation 
achieved (as previously discussed). Based on the results exemplified in Fig. 3, 50 nm mixed-
aptamer-AuNP are used for all subsequent experiments. The investigation of other co-
functionalisation ratios were not explored in this pilot study. However, in future, these may be 







Fig. 3 Comparing the effects of aptamer arrangement on IL-6-induced aggregation of ca. 50 
nm AuNP: single aptamer versus mixed aptamer AuNP functionalisation. All results are 
expressed as extinction at 540 nm normalised to AuNP concentration, to correct for the 
difference in AuNP concentrations between the control and test in (a). Decreasing extinction 
intensity at the λmax (ca. 540 nm) in response to increasing concentrations of IL-6 for the 
single-aptamer AuNP: Amax comparison with control (a). The final concentration of IL-6 in (a) 
is 45.45 μg·mL-1. The control used is a binding control, where IL-6 is titrated into a solution of 
single aptamer-AuNP (with the complimentary binding aptamer missing, as shown in the 
diagram). The response to increasing concentrations of IL-6 are also shown for the mixed-
aptamer-AuNP: Amax comparison with buffer control (b). The final concentration of IL-6 in (b) 
is 42.7 μg·mL-1. Results shown are from a single set of experiments performed on ca. 50 nm 





Aggregation assay results – detecting IL-6 standard solutions 
The performance of the assay, now comprising of 50 nm mixed-aptamer-AuNP, is further 
determined via titrations of increasing concentrations of IL-6 (in buffer). This time a larger IL-
6 concentration range than previously attempted (to a final concentration of 109.4 μg·mL-1) is 
explored. The starting concentration of the 50 nm mixed-aptamer AuNP (prior to addition of 
IL-6) is also increased 5-fold, from ca. 0.01 nM (as used in previous experiments, e.g. as 
shown in Fig. 3b), to ca. 0.05 nM. This change is made with the aim of producing a visual 
colour change.  
Results from a typical experiment are shown in Fig. 4a, b and c. The UV-Vis extinction 
spectrum shows a steady decrease in the intensity of the surface plasmon absorption band at 
ca. 540 nm in response to increasing IL-6 (Fig. 4a). A typical red shift in the extinction 
wavelength maximum of 7 nm is observed in the test solution in this experiment (compared to 
a zero nm shift in the control solution). This shift further confirms the aggregation of the 
aptamer-AuNP in response to IL-6. A comparison between extinction at the λmax (ca. 540 nm) 
in response to either IL-6 or an equal volume of blank buffer is shown in Fig. 4b. There is a 
clear response to increasing IL-6 addition which is readily distinguishable from the dilution 
effect illustrated by the control sample. The aggregation of the aptamer-AuNP is further 
demonstrated in Fig. 4c, which shows the colour change in response to 109.4 μg·mL-1 IL-6 
(compared with the control). Characterisation of the AuNP core, aptamer-functionalised AuNP, 
and control versus IL-6 aggregation test samples was also performed by DLS. The DLS results 
(Fig. 4d) indicate an original hydrodynamic diameter of the AuNP of approximately 50 nm, 
which increases by an estimated 30-40 nm with the addition of aptamers to the AuNP surface. 
Results shown in Fig. 4d are cumulative results from two repeat experiments (see Table S3 
for complete DLS results). In the absence of IL-6, the control sample (in which equal volumes 
of buffer is added instead of IL-6) results in a size estimate comparable to that of the aptamer-
functionalised AuNP, confirming a lack of aggregation. Conversely, in the presence of IL-6, 
large AuNP aggregates estimated at 600 nm in size are formed, confirming successful 





Fig. 4 Aggregation assay (comprising of 50 nm mixed-aptamer-AuNP) results for IL-6 
standard in buffer. Decreasing extinction intensity at the λmax (ca. 540 nm) in response to 
increasing concentrations of IL-6: UV-Vis extinction spectra (a), and extinction at λmax 
comparison with buffer control (b). The visible colour change of the final test solution 
(containing 109.4 μg·mL-1 IL-6) compared with the control sample containing an equivalent 
volume of blank buffer (c). Results shown in a, b and c are from a single experiment, 
representative of all repeats (n = 2). Aptamer-AuNP concentration prior to IL-6 addition is 
estimated at 0.05 nM. Characterisation of the cAuNP core, aptamer-AuNP, test control, and 
the test solution (containing 109.4 μg·mL-1 IL-6) by DLS (d). The size estimates shown are 
based on 10 repeat measurements (n = 2 separate experiments); error bars denote SD of 
repeat measurements 
 
The performance of the aggregation assay is further determined by another titration of 
increasing volumes of IL-6 (to a final concentration of 125 μg·mL-1), but this time in a mixed 
protein solution broadly representative of a biological matrix. The mixed protein solution 
comprises of human serum albumin (HSA) and 36 arbitrary human cytokines and chemokines, 
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notably including human IL-6 (see Table S2 for detailed composition of the matrix). Results 
from a typical experiment are shown in Fig. 5a, b and c. The UV-Vis extinction spectrum, 
showing a steadily decreasing extinction intensity at the λmax (ca. 540 nm) in response to 
increasing IL-6 (comparable to that obtained using IL-6 in buffer, Fig. 5a). A red-shift in the 
λmax of 8.5 nm is again observed in this representative experiment (compared to 1.0 ± 0.5 nm 
for the two controls). The observed shift confirms aggregation of the aptamer-AuNP in 
response to IL-6 without interference from the sample matrix. A comparison between 
extinction at the λmax (ca. 540 nm) in response to either IL-6 or an equal volume of two control 
buffers is shown in Fig. 5b. Here the controls consist of a buffer containing HSA only (‘buffer 
control’), and a buffer containing both HSA and the human protein mix (‘negative control’). The 
aggregation of the aptamer-AuNP in response to IL-6 is again clearly distinguishable from the 
dilution effect seen with both buffers. By separating the response of the ‘negative control’ from 
the ‘buffer’ (dilution effect) control, this result suggests that no obvious cross-reactivity with 
human IL-6 (when present at low concentrations) has occurred during this preliminary test. 
The aggregation of the aptamer-AuNP is further demonstrated in Fig. 5c, which shows the 
colour change in response to IL-6 versus the ‘negative control’. The ‘buffer control’ also does 
not yield a colour change (as shown in Fig. S2). Characterisation of both controls and the IL-
6 aggregation test sample was again performed by DLS. The DLS results (Fig. 5d) show that 
both controls result in a size estimate comparable to that of the aptamer-functionalised AuNP 
(see Fig. 4d), confirming a lack of aggregation. Conversely, in the presence of IL-6, large 
AuNP aggregates of around 500 nm in size are formed, confirming successful aggregation of 









Fig. 5 Aggregation assay (comprising of 50 nm mixed-aptamer-AuNP) results for IL-6 
standard in a broadly representative sample matrix. Decreasing extinction intensity at the 
λmax (ca. 540 nm) in response to increasing concentrations of IL-6: UV-Vis extinction spectra 
(a), and changes in the extinction maxima in comparison with controls (b). The ‘buffer 
control’ contained HSA only; the ‘negative control’ contains both HSA and a mixture of 
human cytokines and chemokines as a representative sample matrix (as listed in Table S2). 
The visible colour change of the final test solution (containing 125 μg·mL-1 IL-6), compared 
with the ‘negative control’ (c). Results shown in a, b and c are from a single experiment, 
representative of all repeats (n = 2). Aptamer-AuNP concentration prior to IL-6 addition is 
estimated at 0.08 nM. Characterisation of the controls and the test solution (containing 125 
μg·mL-1 IL-6) by DLS (d). The size estimates are based on 10 repeat measurements (n = 2 
separate experiments); error bars denote SD of repeat measurements 
 
In this pilot study we have demonstrated the application of this preliminary assay format for 
the detection of IL-6 in the low (1-125) μg·mL-1 range. In biological samples such as mouse 
plasma, IL-6 can be present at concentrations between 1-1500 pg·mL-1 (depending on the 
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health of the animal) [27]. Concentrations of IL-6 in human serum are in the low pg·mL-1 range 
in healthy controls and increase significantly in various disease states. For example, Robak et 
al. reported serum IL-6 concentrations of 0.5 – 16.6 pg·mL-1 in healthy controls and 1.5 – 234 
pg·mL-1 in rheumatoid arthritis patients [28]. In intensive care unit patients with sepsis, Damas 
et al. reported IL-6 serum concentrations of 200 – 461,850 pg·mL-1 [29]. Full optimisation of 
the present assay to achieve a lower limit of detection, and a comparison with current state-
of-the-art point-of-care assays is necessary, but was beyond the scope of this small pilot study. 
There is considerable opportunity for further development and optimisation to achieve a lower 
limit of detection, for example by adapting the concentration of aptamer-AuNP in the test 
solution, or by investigating different co-functionalisation ratios for improved binding efficacy. 
With further optimisation, a test of this nature may be readily applied for the rapid analysis of 
relevant biological samples. Here we have demonstrated the potential of this assay format, 
with a view to future clinical application. This will involve development and complete validation 





In this study, a proof-of-concept aptamer-based assay format for detecting IL-6, a key marker 
of acute inflammation, has been presented. The assay is based on the aggregation of AuNP 
coated in two complimentary “sandwich-style” aptamers, which each bind to different sites on 
the IL-6 peptide. The aggregation of AuNP in the presence of IL-6 induces a visible colour 
change in just 5 minutes, with a corresponding change in extinction intensity at ca. 540 nm 
which can be monitored by spectrophotometer or plate reader. Size increase upon 
aggregation can be also followed by DLS measurements. In this pilot study, key aspects of 
the assay format (AuNP size and aptamer arrangement) are investigated to improve the level 
of aggregation and sensitivity achieved. The assay is successfully applied to the detection of 
murine IL-6 (in the μg·mL-1 range) in buffer, and in a mixed protein solution broadly 
representative of a biological sample matrix. This proof-of-concept study does not, as yet, 
possess the sensitivity to detect the low levels of IL-6 in healthy serum/plasma. More work is 
needed to improve the sensitivity. During infections and sepsis very high levels are known to 
occur in patients (see above). With further development and optimisation to improve the limit 
of detection, this assay format may enable rapid and straightforward detection of acute 
inflammation in either a mouse model, or in mouse-derived cell culture supernatant. This pilot 
study was performed as a proof-of-concept demonstration of aptamer-functionalised AuNP, 
with a view to developing a similar assay targeting human inflammatory markers for analysing 
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patient samples in future. The principle of our assay may, with further development, lead to a 
rapid point-of-care test in patients. 
 
 
Conflict of Interest 




This work was supported by seed-corn funding from the National Institute for Health Research 
Brain Injury Healthcare Technology Co-operative (NIHR-HTC). SGC and KLHC are funded 
from the NIHR Biomedical Research Centre, Cambridge (Neuroscience Theme; Brain Injury 
and Repair Theme). PJH is funded by a NIHR Research Professorship, Academy of Medical 
Sciences/Health Foundation Senior Surgical Scientist Fellowship and the National Institute for 
Health Research Biomedical Research Centre, Cambridge. The authors gratefully 
acknowledge Dr Giorgio Divitini (Department of Materials Science and Metallurgy, University 
of Cambridge) for transmission electron microscope access and assistance, and Prof Yorgo 
Modis and Ms Stephanie Reikine (Department of Medicine, University of Cambridge; 
Molecular Immunity Unit, MRC Laboratory for Molecular Biology) for dynamic light scattering 









[1] Hunter CA, Jones SA (2015), IL-6 as a keystone cytokine in health and disease. Nat Immunol 
16:448-457 
[2] Kumar RG, Boles JA, Wagner AK (2015) Chronic inflammation after severe traumatic brain 
injury: characterization and associations with outcome at 6 and 12 months postinjury. J 
Head Trauma Rehab 30:369-381 
[3] Nwachuku EL, Puccio AM, Adeboye A, Chang Y-F, Kim J, Okonkwo DO (2016) Time course of 
cerebrospinal fluid inflammatory biomarkers and relationship to 6-month neurologic 
outcome in adult severe traumatic brain injury. Clin Neurol Neurosur 149:1-5 
[4] Wu W, Guan Y, Zhao G, Fu X-J, Guo T-Z, Liu Y-T, Ren X-L, Wang W, Liu H-R, Li Y-Q (2016) 
Elevated IL-6 and TNF-α levels in cerebrospinal fluid of subarachnoid hemorrhage patients. 
Mol Neurobiol 53:3277-3285 
[5] Lenski M., Huge V., Briegel J., Tonn J-C, Schichor C, Thon N. (2017) Interleukin 6 in the 
cerebrospinal fluid as a biomarker for onset of vasospasm and ventriculitis after severe 
subarachnoid hemorrhage. World Neurosurg 99:132-139 
[6] Takahashi W, Nakada T-a, Abe R, Tanaka K, Matsumura Y, Oda S (2014) Usefulness of 
interleukin 6 levels in the cerebrospinal fluid for the diagnosis of bacterial meningitis. J Crit 
Care 29:693.e1-6 
[7] Prasad R, Kapoor R, Srivastava R, Mishra OP, Singh TB (2014) Cerebrospinal fluid TNF-α, IL-6, 
and IL-8 in children with bacterial meningitis. Pediatr Neurol 50:60-65 
[8] Bloos F, Reinhart K (2014) Rapid diagnosis of sepsis. Virulence 5:154-160 
[9] Bayer O, Schwarzkopf D, Stumme C, Stacke A, Hartog CS, Hohenstein C, Kabisch B, Reichel J, 
Reinhart K, Winning J (2015) An early warning scoring system to identify septic patients in 
the prehospital setting: the PRESEP score. Acad Emerg Med 22:868-871 
[10] Molano Franco D, Arevalo-Rodriguez I, Roqué i Figuls M and Zamora J (2015) Interleukin-6 
for diagnosis of sepsis in critically ill adult patients. Cochrane Database Syst Rev 7:CD011811 
[11] Mancini N, Carletti S, Ghidoli N, Cichero P, Burioni R, Clementi M (2010) The era of molecular 
and other non-culture-based methods in diagnosis of sepsis. Clin Microbiol Rev 23:235-251 
[12] Hack CE, De Groot ER, Felt-Bersma R, Nuijens JH, Van Schijndel RS, Eerenberg-Belmer A, Thijs 
LG, Aarden LA (1989) Increased plasma levels of interleukin-6 in sepsis. Blood 74:1704-1710 
[13] Chaemsaithong P, Romero R, Korzeniewski SJ, Martinez-Varea A, Dong Z, Yoon BH, Hassan 
SS, Chaiworapongsa T, Yeo L (2016) A rapid interleukin-6 bedside test for the identification 
of intra-amniotic inflammation in preterm labor with intact membranes. J Matern Fetal 
Neonatal Med 29:349-359 
[14] Sefah K, Shangguan D, Xiong X, O'donoghue MB, Tan W (2010) Development of DNA 
aptamers using Cell-SELEX. Nat Protoc 5:1169-1185 
[15] Gopinath SC, Lakshmipriya T, Chen Y, Phang W-M, Hashim U (2016) Aptamer-based 'point-
of-care testing'. Biotechnol Adv 34:198-208 
[16] Toh SY, Citartan M, Gopinath SC, Tang T-H (2015) Aptamers as a replacement for antibodies 
in enzyme-linked immunosorbent assay. Biosens Bioelectron 64:392-403 
[17] Marín MJ, Rashid A, Rejzek M, Fairhurst SA, Wharton SA, Martin SR, McCauley JW, Wileman 
T, Field RA, Russell DA (2013) Glyconanoparticles for the plasmonic detection and 
discrimination between human and avian influenza virus. Org Biomol Chem 11:7101-7107 
[18] Pavlov V, Xiao Y, Shlyahovsky B, Willner I (2004) Aptamer-functionalized Au nanoparticles for 
the amplified optical detection of thrombin. J Am Chem Soc 126:11768-11769 
[19] Marín MJ, Schofield CL, Field RA, Russell DA (2015) Glyconanoparticles for colorimetric 
bioassays. Analyst 140:59-70 
[20] Sabela M, Balme S, Bechelany M, Janot JM, Bisetty K (2017) A review of gold and silver 
nanoparticle-based colorimetric sensing assays. Adv Eng Mater 19:1700270 
[21] Giorgi-Coll S., Blunt-Foley H., Hutchinson PJ, Carpenter KL (2017) Heparin-gold nanoparticles 
for enhanced microdialysis sampling. Analytical and bioanalytical chemistry. 409:5031-5042 
21 
 
[22] Turkevich J, Stevenson PC, Hillier J (1953) The formation of colloidal gold. J Phys Chem 
57:670-673 
[23] Bastús NG, Comenge J, Puntes V (2011) Kinetically controlled seeded growth synthesis of 
citrate-stabilized gold nanoparticles of up to 200 nm: size focusing versus ostwald ripening. 
Langmuir 27:11098-11105 
[24] Zhang X, Servos MR, Liu J (2012) Instantaneous and quantitative functionalization of gold 
nanoparticles with thiolated DNA using a pH-assisted and surfactant-free route. J Am Chem 
Soc 134:7266-7269 
[25] Marín MJ, Rackham BD, Round AN, Howell LA, Russell DA, Searcey M (2013) A rapid screen 
for molecules that form duplex to duplex crosslinks in DNA. Chem Commun 49:9113-9115 
[26] Krpetić Ž, Guerrini L, Larmour IA, Reglinski J, Faulds K, Graham D (2012) Importance of 
nanoparticle size in colorimetric and SERS-based multimodal trace detection of Ni(II) ions 
with functional gold nanoparticles. Small 8:707-714. 
[27] Nukina H, Sudo N, Aiba Y, Oyama N, Koga Y, Kubo C (2001) Restraint stress elevates the 
plasma interleukin-6 levels in germ-free mice. J Neuroimmunol 115:46-52. 
[28] Robak T, Gladalska A, Stepien ́H, Robak E (1998) Serum levels of interleukin-6 type cytokines 
and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Mediators Inflamm 
7: 347–353. 
[29] Damas P, Ledoux D, Nys M, Vrindts Y, De Groote D, Franchimont P, Lamy M (1992) Cytokine 
serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 215:356-
362. 
 
 
